CVAC
HealthcareCureVac N.V.
$4.66
$-0.01 (-0.21%)
Jan 5, 2026
Price History (1Y)
Analysis
CureVac N.V. is a biotechnology company operating in the healthcare sector. With a market capitalization of $1.05B and annual revenue of $70.74M, the company has a significant presence in its industry. It employs approximately 825 individuals. The company's financial performance reveals high profitability, with gross margin reaching 93.3% and profit margin exceeding 182.1%. However, operating margin is notably high at 573.0%, suggesting cost efficiency. The balance sheet shows relatively low debt of $35.07M compared to cash reserves of $416.09M, resulting in a debt-to-equity ratio of 4.03. CureVac N.V.'s valuation can be assessed through its price-to-earnings (P/E) ratio, which stands at 6.96 on a trailing-twelve-month basis but turns negative at -8.02 for the forward period, indicating potential volatility in earnings growth. Revenue has decreased by 89.0% year-over-year, while earnings have grown by 24.0%. The company does not pay dividends, as indicated by a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About CureVac N.V.
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was incorporated in 2000 and is headquartered in Tübingen, Germany.
Key Statistics
- Market Cap
- $1.05B
- P/E Ratio
- 6.96
- 52-Week High
- $5.72
- 52-Week Low
- $2.48
- Avg Volume
- 1.13M
- Beta
- 1.84
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- Germany
- Employees
- 825